Idiopathic Pulmonary Fibrosis is a diffuse progressive parenchymal lung disease of unknown etiology, characterised by fibrotic interstitial infiltrates. While the course of the disease is variable, the prognosis is uniformly poor, with median survival of about 3-5 years after diagnosis. As the interstitial fibrosis and architectural distortion of the lung advance, the lung becomes increasingly non-compliant and the work of breathing and dyspnea increase.
Patients with IPF typically experience slow progressive worsening of lung function over time but some experience rapid declines and frequent hospitalisations in the late stages of the disease. IPF is the most common type of interstitial lung disease, estimated to affect between 132,000 and 200,000 people in the US. It is typically seen in older adults, more commonly in men than women, and usually occurs between 50 and 70 years of age.
LAMELLASOME™ IPF-NA is a novel antifibrotic for the treatment of Idiopathic Pulmonary Fibrosis (IPF). It will be delivered topically to the lung to regulate the alveolar inflammatory response and disrupt the progressive chronic fibrosis.
||The active agent within LAMELLASOME™ IPF-NA balances the regulation of fibrosis within the lung||
|SAFETY||LAMELLASOME™ respiratory safety||Non-clinical respiratory safety program on LAMELLASOME™ completed demonstrating an excellent safety and tolerability profile||
Existing treatments of IPF have sub-optimal efficacy with continued loss of quality of life and a median survival of 3-5 years after diagnosis. The pathology of the disease is driven by progressive chronic fibrosis. LAMELLASOME™ IPF-NA regulates the alveolar inflammatory response by disrupting progressive chronic fibrosis offering a significant advance in efficacy over existing treatments.
Idiopathic Pulmonary Fibrosis (IPF) qualifies as an orphan disease indication in both the EU & US. Consequently, LAMELLASOME™ IPF-NA is expected to benefit from an accelerated development program and expedited regulatory review.